BioLineRx (BLRX) Operating Income (2013 - 2025)
BioLineRx (BLRX) posted Operating Income of -$3.4 million for Q4 2025, down 53.42% on a QoQ basis from -$2.2 million in Q3 2025, and up 23.5% year-over-year from -$2.7 million in Q4 2024.
BioLineRx (BLRX) has 13 years of Operating Income data on file, last reported at -$3.4 million in Q4 2025.
- In Q4 2025, Operating Income rose 23.5% year-over-year to -$3.4 million; the TTM figure through Dec 2025 stood at -$10.3 million (up 49.59% YoY), while the FY2025 annual figure was -$10.3 million, up 49.59% from the prior year.
- Operating Income retreated to -$3.4 million in Q4 2025, from -$2.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.2 million in Q3 2025 and bottomed at -$18.6 million in Q4 2023.
- A 5-year average of -$6.7 million and a median of -$6.1 million in 2021 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income sank 121.08% — and 2024, when it surged 76.16%.
- Year by year, Operating Income stood at -$6.6 million in 2021, then fell by 27.28% to -$8.4 million in 2022, then sank by 121.08% to -$18.6 million in 2023, then surged by 76.16% to -$4.4 million in 2024, then gained by 23.5% to -$3.4 million in 2025.
- The last three Operating Income figures came in at -$3.4 million (Q4 2025), -$2.2 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -3.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -2.21 Mn |
| Jun 30, 2025 | -2.30 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -5.39 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -18.57 Mn |
| Sep 30, 2023 | -12.36 Mn |
| Jun 30, 2023 | -9.92 Mn |
| Mar 31, 2023 | -8.86 Mn |
| Dec 31, 2022 | -8.40 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -7.60 Mn |
| Mar 31, 2022 | -6.08 Mn |
| Dec 31, 2021 | -6.60 Mn |
| Sep 30, 2021 | -6.22 Mn |
| Jun 30, 2021 | -6.51 Mn |
| Mar 31, 2021 | -5.45 Mn |
| Dec 31, 2020 | -5.87 Mn |
| Sep 30, 2020 | -4.65 Mn |
| Jun 30, 2020 | -5.57 Mn |
| Mar 31, 2020 | -6.84 Mn |
| Dec 31, 2019 | -9.41 Mn |
| Sep 30, 2019 | -6.64 Mn |
| Jun 30, 2019 | -6.48 Mn |
| Mar 31, 2019 | -5.58 Mn |
| Dec 31, 2018 | -7.04 Mn |
| Sep 30, 2018 | -6.21 Mn |
| Jun 30, 2018 | -5.73 Mn |
| Mar 31, 2018 | -6.63 Mn |
| Dec 31, 2017 | -7.69 Mn |
| Sep 30, 2017 | -7.06 Mn |
| Jun 30, 2017 | -5.19 Mn |
| Mar 31, 2017 | -5.30 Mn |
| Dec 31, 2016 | -4.38 Mn |
| Sep 30, 2016 | -4.49 Mn |
| Jun 30, 2016 | -3.87 Mn |
| Mar 31, 2016 | -3.78 Mn |
| Dec 31, 2015 | -4.10 Mn |
| Sep 30, 2015 | -3.60 Mn |
| Jun 30, 2015 | -4.17 Mn |
| Mar 31, 2015 | -4.33 Mn |
| Dec 31, 2014 | -5.20 Mn |
| Sep 30, 2014 | -4.07 Mn |
| Jun 30, 2014 | -3.91 Mn |
| Mar 31, 2014 | -4.08 Mn |
| Dec 31, 2013 | -2.29 Mn |
| Sep 30, 2013 | -3.28 Mn |
| Jun 30, 2013 | -4.63 Mn |
| Mar 31, 2013 | -6.51 Mn |